Cisplatin is one of the major causes of acute kidney injury (AKI) in clinical practice, and ferroptosis is an essential form of cell death in cisplatin-induced AKI (CP-AKI). WW domain binding protein-2 (WBP2), a molecular chaperon, is involved in the progression of various malignancies, but its role in renal injuries has not been investigated. Our present study employed bioinformatics analysis to identify WBP2 as a potential modulator of AKI and ferroptosis. Preliminary laboratory investigations showed that WBP2, highly expressed in renal proximal tubular cells, was downregulated in CP-AKI. Further studies demonstrated that WBP2 decelerated ferroptosis to alleviate CP-AKI. Mechanistically, WBP2 interacted with glutathione peroxidase 4 (GPX4, a key detoxicating enzyme for ferroptosis) via its PPXY1 motif to inhibit ferroptosis. Furthermore, the in-depth investigations revealed that WBP2 competed with heat shock cognate protein 70 (HSC70) for the binding with the KEFRQ-like motifs of GPX4, leading to the deceleration of chaperon-mediated autophagy of GPX4. All in all, this study indicated the beneficial effect of WBP2 in CP-AKI and its relevance with ferroptosis, thus providing a novel insight into the modulation of ferroptosis in cisplatin-related nephropathy.
Objective. This paper aims to explore novel ferroptosis‐related biomarkers for acute kidney injury (AKI). Methods. Various bioinformatic methods, such as differential expression analysis, functional annotation analysis, machine learning, and chemical‐gene network analysis, were used in this study. Furthermore, the expression and proferroptotic role of RPS7 were validated with further bioinformatics analysis and biochemical experiments. Results. GSE30718 dataset and GSE139061 dataset were used, and the differentially expressed genes (DEGs) were screened. The DEGs were overlapped with ferroptosis‐related genes and genes associated with AKI, which led to the identification of four candidate genes. Machine learning and ROC curve analysis were conducted, and RPS7 and TRIB3 were selected for diagnostic model analysis and functional analysis. Finally, the upregulation of RSP7 in cisplatin‐induced AKI was validated in cisplatin‐induced AKI, and its proferroptotic role was confirmed in cisplatin‐treated proximal tubular cells. Conclusion. Our results indicated that RPS7 might present as a novel ferroptosis‐related biomarker for AKI, and it derived ferroptosis to accentuate cisplatin‐induced AKI.
25 July 2025 in Journal of the American Society of Nephrology
Key Points: Keratin 20 was upregulated earlier than kidney injury molecule 1 in AKI, and its proximal tubule–specific deletion aggravated kidney dysfunction in mouse models. Keratin 20 competed with apoptosis-linked gene-2-interacting protein X for peroxiredoxin 2 binding, thereby decreasing the exosomal secretion of peroxiredoxin 2 and inhibiting ferroptosis in kidney tubular cells. Background: AKI is a prevalent clinical syndrome with insufficient kidney function. Keratin 20 (KRT20), a component of intermediate filaments, is widely recognized as a biomarker of kidney tubular injury, yet its exact function in kidney disease remains uncertain. Methods: RNA sequencing data from a mouse model of ischemia/reperfusion-induced AKI were analyzed to assess KRT20 transcript levels. The effect of specific Krt20 knockout in renal proximal tubule cells ( Krt20PTKO ) was subsequently examined in two distinct AKI mouse models. Luciferase reporter assays and chromatin immunoprecipitation–PCR was used to identify transcription factors regulating KRT20 expression, whereas immunoprecipitation followed by mass spectrometry elucidated the downstream targets of KRT20. In addition, the clinical significance of KRT20 and peroxiredoxin 2 (PRDX2) was evaluated in patients with acute tubular necrosis. Results: KRT20 was significantly upregulated in renal proximal tubule cells during the early phase of AKI, preceding the induction of kidney injury molecule 1 expression. This upregulation was mediated by FBJ Murine Osteosarcoma Viral Oncogene Homolog B in both ischemia/reperfusion and cisplatin-induced AKI models. Renal proximal tubule cell–specific knockout of Krt20 exacerbated the kidney injury during AKI. Mechanistically, KRT20 protected against AKI by sequestering PRDX2, an antioxidant protein, and inhibiting the exosomal secretion of PRDX2, eventually preventing ferroptosis in kidney tubular cells. Further analysis revealed that apoptosis-linked gene-2-interacting protein X facilitated PRDX2 exosomal release, whereas KRT20 competed with apoptosis-linked gene-2-interacting protein X for binding to the N -terminal domain of PRDX2, thereby retaining PRDX2 intracellularly. Finally, the expression levels of KRT20 and PRDX2 were correlated with kidney injury severity and kidney function decline in clinical samples. Conclusions: These findings indicate that KRT20 was upregulated in the early stages of AKI, serving to protect kidney tubule cells by sequestering PRDX2 and inhibiting ferroptosis.